Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting No phase listed Observational

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

ClinicalTrials.gov ID: NCT06988618

Public ClinicalTrials.gov record NCT06988618. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Study identification

NCT ID
NCT06988618
Recruitment status
Recruiting
Study type
Observational
Phase
Not listed
Lead sponsor
Galderma R&D
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 11, 2025 (Actual)
Primary completion
Nov 30, 2027 (Estimated)
Completion
Nov 30, 2027 (Estimated)
Last update posted
Sep 9, 2026

2025 – 2027

United States locations

U.S. sites
39
U.S. states
18
U.S. cities
37
Facility City State ZIP Site status
Galderma Investigational Site # 8893 Birmingham Alabama 35244 Recruiting
Galderma Investigational Site # 7077 Phoenix Arizona 85006-2754 Recruiting
Galderma Investigational Site # 7060 Phoenix Arizona 85008-3884 Recruiting
Galderma Investigational Site # 7067 Tucson Arizona 85718 Recruiting
Galderma Investigational Site # 7074 Corona California 92882 Recruiting
Galderma Investigational Site # 6836 Fountain Valley California 92708-3701 Recruiting
Galderma Investigational Site # 8224 Fremont California 94538-1603 Recruiting
Galderma Investigational Site # 7064 Santa Monica California 90404-2216 Recruiting
Galderma Investigational Site # 7061 Castle Rock Colorado 80109-8034 Recruiting
Galderma Investigational Site # 7059 Fairfield Connecticut 06824 Recruiting
Galderma Investigational Site # 7087 Coral Gables Florida 33134 Recruiting
Galderma Investigational Site # 7063 Cutler Bay Florida 33157 Recruiting
Galderma Investigational Site # 7078 Miami Florida 33173 Recruiting
Galderma Investigational Site # 7070 North Miami Beach Florida 33162-4708 Recruiting
Galderma Investigational Site # 7091 Tampa Florida 33615-4537 Recruiting
Galderma Investigational Site # 7058 Chicago Illinois 60641 Not yet recruiting
Galderma Investigational Site # 8142 Indianapolis Indiana 46250-2041 Recruiting
Galderma Investigational Site # 8012 Glendale Maryland 20769-9182 Recruiting
Galderma Investigational Site # 7068 Rockville Maryland 20850-6243 Recruiting
Galderma Investigational Site # 7065 Brighton Massachusetts 02135 Recruiting
Galderma Investigational Site # 7066 Auburn Hills Michigan 48326-3396 Recruiting
Galderma Investigational Site # 7071 Caledonia Michigan 49316-7478 Recruiting
Galderma Investigational Site # 7072 Troy Michigan 48084-5260 Recruiting
Galderma Investigational Site # 7053 Waterford Michigan 48328 Recruiting
Galderma Investigational Site # 7057 Lee's Summit Missouri 64064 Recruiting
Galderma Investigational Site # 7076 St Louis Missouri 63141-7068 Recruiting
Galderma Investigational Site # 7055 Portsmouth New Hampshire 03801-7156 Recruiting
Galderma Investigational Site # 7080 Auburn New York 13021 Recruiting
Galderma Investigational Site # 7052 East Syracuse New York 13057 Recruiting
Galderma Investigational Site # 8282 Mount Kisco New York 10549-3035 Recruiting
Galderma Investigational Site # 7056 New York New York 10012-1354 Recruiting
Galderma Investigational Site # 7051 New York New York 10023 Recruiting
Galderma Investigational Site # 7081 Dayton Ohio 45414-2799 Recruiting
Galderma Investigational Site # 8559 Philadelphia Pennsylvania 19103-4738 Recruiting
Galderma Investigational Site # 8238 Dallas Texas 75230-5808 Recruiting
Galderma Investigational Site # 7062 Edinburg Texas 78539-4660 Recruiting
Galderma Investigational Site # 7088 Grapevine Texas 76051 Recruiting
Galderma Investigational Site # 7069 Sugar Land Texas 77478-3842 Recruiting
Galderma Investigational Site # 7079 Vienna Virginia 22182 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06988618, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2026 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06988618 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →